Expenditure and value for money: The challenge of implantable cardioverter defibrillators

QJM: An International Journal of Medicine

Volumn 102, Issue 5, 2009, Pages 349-356

  Boriani, Giuseppe ^a   Biffi, M ^a   Martignani, C ^a   Diemberger, I ^a   Valzania, C ^a   Bertini, M ^a   Branzi, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEFIBRILLATOR; DRUG COST; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; META ANALYSIS; OVERALL SURVIVAL; PATIENT SELECTION; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; SUDDEN DEATH; SYSTEMATIC REVIEW; TREATMENT INDICATION;

COST-BENEFIT ANALYSIS; DEFIBRILLATORS, IMPLANTABLE; EVIDENCE-BASED MEDICINE; HEALTH CARE COSTS; HEART FAILURE; HUMANS;

EID: 65449128183     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcp025     Document Type: Article

References (43)

1. Krumholz HM, Weintraub WS, Bradford WD, Heidenreich PA, Mark DB, Paltiel AD. Task force #2 - the cost of prevention: Can we afford it? Can we afford not to do it? 33rd Bethesda Conference. J Am Coll Cardiol 2002; 40:603-15.
2. Boriani G, Biffi M, Martignani C, Camanini C, Grigioni F, Rapezzi C, et al. Cardioverter-defibrillators after MADIT-II: The balance between weight of evidence and treatment costs. Eur J Heart Failure 2003; 5:419-25.
3. Stevenson LW. Implantable cardioverter-defibrillators for primary prevention of sudden death in heart failure: Are there enough bangs for the bucks? Circulation 2006; 114:101-3.
4. Raffle AE. Challenges of implementing human papillomavirus (HPV) vaccination policy. Br Med J 2007; 335:375-7.
5. Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Goodman MJ, Solberg LI. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med 2006; 31:52-61.
6. Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, et al. Task Force on Sudden Cardiac Death. Euro Soc Cardiol. Europace 2002; 4:3-18.
7. Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: A pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 2004; 44:2166-72.
8. Al-Khatib SM, Sanders GD, Mark DB, Lee KL, Bardy GH, Bigger JT, et al Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J 2005; 149 1020-34.
9. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology. Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). Eur Heart J 2006; 27:2099-140.
10. Rossenbacker T, Priori SG, Zipes DP. The fight against sudden cardiac death: Consensus guidelines as a reference. Eur Heart J Suppl 2007; 9:150-8.
11. Ezekowitz JA, Rowe BH, Dryden DM, Hooton N, Vandermeer B, Spooner C, et al. Systematic review: Implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med 2007; 147:251-62.
12. Smith TW, Cain ME. Sudden cardiac death: Epidemiologic and financial worldwide perspective. J Interv Card Electrophysiol 2006; 17 199-203.
13. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001; 104:2158-63.
14. Mehra R. Global public health problem of sudden cardiac death. J Electrocardiol 2007; 40:S118-22.
15. Hammill SC, Stevenson LW, Kadish AH, Kremers MS, Heidenreich P, Lindsay BD, et al. Review of the registry's first year, data collected, and future plans. Heart Rhythm 2007; 4:1260-3.
16. Sweeney MO, Schoenfeld MH, Cannom DS. Rules of evidence: CMS and primary prevention of sudden cardiac death in systolic heart failure. Pacing Clin Electrophysiol 2005; 28:81-8.
17. Ector H, Vardas P. on behalf of the European Heart Rhythm Association, European Society of Cardiology. Current use of pacemakers, implantable cardioverter defibrillators, and resynchronization devices: Data from the registry of the European Heart Rhythm Association. Eur Heart J Suppl 2007; 9:144-9.
18. Boriani G, Biffi M, Martignani C, Gallina M, Branzi A. Cost-effectiveness of implantable cardioverter-defibrillators. Eur Heart J 2001; 22:990-6.
19. Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF, et al Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980; 303 322-4.
20. Meltzer MI. Introduction to health economics for physicians. Lancet 2001; 358:993-8.
21. Priori SG, Klein W, Bassand JP. Medical Practice Guidelines. Separating science from economics. Eur Heart J 2003; 24:1962-4.
22. Ryden L, Stokoe G, Breithardt G, Lindemans F, Potgieter A. Patient access to medical technology across Europe. Eur Heart J 2004; 25:611-6.
23. Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15:369-90.
24. Kupersmith J. Cost-effectiveness strategies in cardiology. In: Alexander RW, Schlant RC, Fuster V, O'Rourke RA, Roberts R, Sonnenblick EH, Hurst's The Heart Arteries and Veins. 9th edn. New York, McGraw Hill, 1998:2257-78.
25. Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997; 336:332-6.
26. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002; 346:1800-6.
27. Al-Khatib SM, Anstrom KJ, Eisenstein EL, Peterson ED, Jollis JG, Mark DB, et al. Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med 2005; 142:593-600.
28. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005; 353:1471-80.
29. Calvert MJ, Freemantle N, Yao G, Cleland JG, Billingham L, Daubert JC, Bryan S. CARE-HF investigators. Cost-effectiveness of cardiac resynchronization therapy: Results from the CARE-HF trial. Eur Heart J 2005; 26:2681-8.
30. Feldman AM, de Lissovoy G, Bristow MR, Saxon LA, De Marco T, Kass DA, et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005; 46 2311-21.
31. Zwanziger J, Hall WJ, Dick AW, Zhao H, Mushlin AI, Hahn RM, et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006; 47:2310-8.
32. Mark DB, Nelson CL, Anstrom KJ, Al-Khatib SM, Tsiatis AA, Cowper PA, et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: Results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2006; 114:135-42.
33. Bryant J, Brodin H, Loveman E, Payne E, Clegg A. The clinical and cost-effectiveness of implantable cardioverter defibrillators: A systematic review. Health Technol Assess 2005; 9:1-150.
34. Bryant J, Brodin H, Loveman E, Clegg A. Clinical effectiveness and cost-effectiveness of implantable cardioverter defibrillators for arrhythmias: A systematic review and economic evaluation. Int J Technol Assess Health Care 2007; 23:63-70.
35. Caro JJ, Ward A, Deniz HB, O'Brien JA, Ehreth JL. Cost-benefit analysis of preventing sudden cardiac deaths with an Implantable Cardioverter Defibrillator (ICD) vs. Amiodarone. Value Health 2007; 10 13-22.
36. Boriani G. Cardioverter defibrillators in primary prevention of sudden cardiac death: A cost or an investment? Value Health 2007; 10 1-2.
37. Boriani G, Biffi M, Russo M, Lunati M, Botto G, Proclemer A, et al Primary prevention of sudden cardiac death: Can we afford the cost of cardioverter-defibrillators? Data from the Search-MI Registry-Italian Sub-study. Pacing Clin Electrophysiol 2006; 29(Suppl. 2) S29-34.
38. Chan PS, Stein K, Chow T, Fendrick M, Bigger JT, Vijan S. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population. J Am Coll Cardiol 2006; 48 112-21.
39. Jung W, Schumacher B. What is the role of risk stratification for sudden death in the defibrillator era? Eur Heart J Suppl 2007; 9 159-65.
40. Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. Am Heart J 2002; 144:440-8.
41. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: The ISPOR RCT-CEA Task Force report. Value Health 2005; 8:521-33.
42. Sutton R, Fisher JD, Linde C, Benditt DG. History of electrical therapy for the heart. Eur Heart J Suppl 2007; 9:I3-I10.
43. National Institute for Health and Clinical Excellence. A guide to NICE. London. April 2005: 1-18.